$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr

$csbr Overview Financials Valuation SEC Filings Company Website

2018 Q3 Form 10-Q Financial Statement

#000162828018011874 Filed on September 14, 2018

Income Statement

Concept	2018 Q3	2017 Q3
Revenue	$6.225M	$5.033M
YoY Change	23.68%	37.14%
Cost Of Revenue	$3.083M	$2.642M
YoY Change	16.69%	4.84%
Gross Profit	$3.142M	$2.391M
YoY Change	31.41%	107.91%
Gross Profit Margin	50.47%	47.51%
Selling, General & Admin	$1.573M	$1.892M
YoY Change	-16.86%	-23.06%
% of Gross Profit	50.06%	79.13%
Research & Development	$1.088M	$1.118M
YoY Change	-2.68%	-7.68%
% of Gross Profit	34.63%	46.76%
Depreciation & Amortization	$111.0K	$36.00K
YoY Change	208.33%	-7.69%
% of Gross Profit	3.53%	1.51%
Operating Expenses	$5.744M	$5.652M
YoY Change	1.63%	-8.74%
Operating Profit	$481.0K	-$619.0K
YoY Change	-177.71%	-75.47%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$1.000K	-$51.00K
YoY Change	-101.96%	466.67%
Pretax Income	$482.0K	-$670.0K
YoY Change	-171.94%	-73.54%
Income Tax	$0.00	$4.000K
% Of Pretax Income	0.0%
Net Earnings	$483.0K	-$674.0K
YoY Change	-171.66%	-73.53%
Net Earnings / Revenue	7.76%	-13.39%
Basic Earnings Per Share	$0.04	-$0.06
Diluted Earnings Per Share	$0.04	-$0.06
COMMON SHARES
Basic Shares Outstanding	11.01M shares	10.98M shares
Diluted Shares Outstanding	12.62M shares	10.98M shares

Balance Sheet

Concept	2018 Q3	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.020M	$430.0K
YoY Change	137.21%	-90.36%
Cash & Equivalents	$1.000M	$400.0K
Short-Term Investments
Other Short-Term Assets	$250.0K	$360.0K
YoY Change	-30.56%	2.86%
Inventory
Prepaid Expenses
Receivables	$3.769M	$2.667M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$5.031M	$3.457M
YoY Change	45.53%	-46.32%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.425M	$2.084M
YoY Change	16.36%	253.22%
Goodwill	$669.0K	$669.0K
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$116.0K	$107.0K
YoY Change	8.41%	-28.67%
Total Long-Term Assets	$3.360M	$3.010M
YoY Change	11.63%	113.63%
TOTAL ASSETS
Total Short-Term Assets	$5.031M	$3.457M
Total Long-Term Assets	$3.360M	$3.010M
Total Assets	$8.391M	$6.467M
YoY Change	29.75%	-17.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.119M	$1.732M
YoY Change	22.34%	14.78%
Accrued Expenses	$366.0K	$551.0K
YoY Change	-33.58%	150.45%
Deferred Revenue	$4.263M
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$140.0K	$30.00K
YoY Change	366.67%
Total Short-Term Liabilities	$6.885M	$6.020M
YoY Change	14.37%	36.01%
LONG-TERM LIABILITIES
Long-Term Debt	$150.0K	$30.00K
YoY Change	400.0%
Other Long-Term Liabilities	$151.0K	$157.0K
YoY Change	-3.82%	-36.44%
Total Long-Term Liabilities	$151.0K	$157.0K
YoY Change	-3.82%	-36.44%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.885M	$6.020M
Total Long-Term Liabilities	$151.0K	$157.0K
Total Liabilities	$7.789M	$6.177M
YoY Change	26.1%	32.18%
SHAREHOLDERS EQUITY
Retained Earnings	-$70.34M	-$70.02M
YoY Change	0.46%	7.71%
Common Stock	$72.20M	$71.57M
YoY Change	0.88%	3.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.252M	$1.252M
YoY Change	0.0%	0.0%
Treasury Stock Shares	269.7K shares	269.7K shares
Shareholders Equity	$603.0K	$290.0K
YoY Change
Total Liabilities & Shareholders Equity	$8.391M	$6.467M
YoY Change	29.75%	-17.61%

Cashflow Statement

Concept	2018 Q3	2017 Q3
OPERATING ACTIVITIES
Net Income	$483.0K	-$674.0K
YoY Change	-171.66%	-73.53%
Depreciation, Depletion And Amortization	$111.0K	$36.00K
YoY Change	208.33%	-7.69%
Cash From Operating Activities	$336.0K	-$1.948M
YoY Change	-117.25%	-20.13%
INVESTING ACTIVITIES
Capital Expenditures	$211.0K	$910.0K
YoY Change	-76.81%	5252.94%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$211.0K	-$910.0K
YoY Change	-76.81%	5252.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$35.00K	-$7.000K
YoY Change	-600.0%	-100.16%
NET CHANGE
Cash From Operating Activities	$336.0K	-$1.948M
Cash From Investing Activities	-$211.0K	-$910.0K
Cash From Financing Activities	$35.00K	-$7.000K
Net Change In Cash	$160.0K	-$2.865M
YoY Change	-105.58%	-252.56%
FREE CASH FLOW
Cash From Operating Activities	$336.0K	-$1.948M
Capital Expenditures	$211.0K	$910.0K
Free Cash Flow	$125.0K	-$2.858M
YoY Change	-104.37%	16.37%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q2	csbr	Assetsin Progress Gross AssetsinProgressGross	15000	USD
CY2018Q3	csbr	Assetsin Progress Gross AssetsinProgressGross	58000	USD
CY2018Q3	csbr	Capital Lease Obligations Noncurrent Excluding Interest CapitalLeaseObligationsNoncurrentExcludingInterest	129000	USD
CY2014Q4	csbr	Monthly Capital Lease Payment MonthlyCapitalLeasePayment	3000	USD
CY2018Q3	csbr	Monthly Capital Lease Payment MonthlyCapitalLeasePayment	11000	USD
CY2018Q3	csbr	Numberof Operating Subsidiaries NumberofOperatingSubsidiaries	2	subsidiary
CY2017Q3	csbr	Reversalof Provisionfor Doubtful Accounts ReversalofProvisionforDoubtfulAccounts	14000	USD
CY2018Q3	csbr	Reversalof Provisionfor Doubtful Accounts ReversalofProvisionforDoubtfulAccounts	0	USD
CY2018Q3	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Aggregate Intrinsic Value Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted	1000	USD
CY2018Q3	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grant In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm	P5Y9M18D
CY2018Q3	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Canceled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod	0	shares
CY2018Q3	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P9Y10M25D
CY2018Q3	csbr	Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstanding	2004284	shares
CY2018Q3	csbr	Share Based Compensation Arrangements By Share Based Payment Award Options Canceled In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice	0.00
CY2018Q3	csbr	Working Capital Deficit WorkingCapitalDeficit	1900000	USD
CY2018Q3	dei	Amendment Flag AmendmentFlag	false
CY2018Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--04-30
CY2018Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2018Q3	dei	Document Period End Date DocumentPeriodEndDate	2018-07-31
CY2018Q3	dei	Document Type DocumentType	10-Q
CY2018Q3	dei	Entity Central Index Key EntityCentralIndexKey	0000771856
CY2018Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11164442	shares
CY2018Q3	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2018Q3	dei	Entity Registrant Name EntityRegistrantName	CHAMPIONS ONCOLOGY, INC.
CY2018Q3	dei	Trading Symbol TradingSymbol	CSBR
CY2018Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2154000	USD
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2119000	USD
CY2018Q2	us-gaap	Accounts Receivable Gross AccountsReceivableGross	1827000	USD
CY2018Q3	us-gaap	Accounts Receivable Gross AccountsReceivableGross	1153000	USD
CY2018Q2	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	3930000	USD
CY2018Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	3782000	USD
CY2018Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3917000	USD
CY2018Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3769000	USD
CY2018Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	569000	USD
CY2018Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	366000	USD
CY2018Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1468000	USD
CY2018Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1586000	USD
CY2018Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	72070000	USD
CY2018Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	72187000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	564000	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	83000	USD
CY2018Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	13000	USD
CY2018Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	13000	USD
CY2017Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4506090	shares
CY2018Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4691379	shares
CY2018Q2	us-gaap	Assets Assets	8078000	USD
CY2018Q3	us-gaap	Assets Assets	8391000	USD
CY2018Q2	us-gaap	Assets Current AssetsCurrent	5060000	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	5031000	USD
CY2018Q2	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	26000	USD
CY2018Q3	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	137000	USD
CY2017Q3	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2018Q3	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	249000	USD
CY2018Q2	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	17000	USD
CY2018Q3	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	148000	USD
CY2018Q2	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	130000	USD
CY2018Q3	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	379000	USD
CY2018Q3	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	285000	USD
CY2018Q3	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	137000	USD
CY2018Q3	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	33000	USD
CY2018Q3	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	143000	USD
CY2018Q3	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	19000	USD
CY2018Q3	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	266000	USD
CY2018Q3	us-gaap	Capital Leases Future Minimum Payments Remainder Of Fiscal Year CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear	109000	USD
CY2018Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	973000	USD
CY2018Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1001000	USD
CY2018Q2	us-gaap	Cash Cash	856000	USD
CY2018Q3	us-gaap	Cash Cash	1016000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	856000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1016000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1000000	USD
CY2017Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3445000	USD
CY2017Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	580000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1006000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1166000	USD
CY2017Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2865000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	160000	USD
CY2018Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	USD
CY2018Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	USD
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11277675	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11297675	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11003228	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11027990	shares
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	11000	USD
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	11000	USD
CY2018Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	4704000	USD
CY2018Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	4263000	USD
CY2018Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4704000	USD
CY2018Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4263000	USD
CY2017Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2642000	USD
CY2018Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3083000	USD
CY2018Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	454000	USD
CY2018Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	605000	USD
CY2017Q3	us-gaap	Depreciation Depreciation	36000	USD
CY2018Q3	us-gaap	Depreciation Depreciation	111000	USD
CY2017Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	42000	USD
CY2018Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	118000	USD
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2018Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2018Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.04
CY2018Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	432422	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	482000	USD
CY2018Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y9M18D
CY2018Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	73000	USD
CY2018Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	74000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1209000	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1055000	USD
CY2018Q2	us-gaap	Goodwill Goodwill	669000	USD
CY2018Q3	us-gaap	Goodwill Goodwill	669000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-670000	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-120000	USD
CY2018Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-43000	USD
CY2017Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	407000	USD
CY2018Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-148000	USD
CY2017Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-134000	USD
CY2018Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-203000	USD
CY2017Q3	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1173000	USD
CY2018Q3	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-441000	USD
CY2017Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	60000	USD
CY2018Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-41000	USD
CY2017Q3	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	0	USD
CY2018Q3	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	-151000	USD
CY2017Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2018Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	1605740	shares
CY2017Q3	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2018Q3	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	8000	USD
CY2017Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	102000	USD
CY2018Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	188000	USD
CY2018Q2	us-gaap	Liabilities Liabilities	8075000	USD
CY2018Q3	us-gaap	Liabilities Liabilities	7789000	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8078000	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8391000	USD
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	7453000	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6885000	USD
CY2017Q4	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	1500000	USD
CY2018Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	2490000	USD
CY2018Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	2878000	USD
CY2017Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-7000	USD
CY2018Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	35000	USD
CY2017Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-910000	USD
CY2018Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-211000	USD
CY2017Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1948000	USD
CY2018Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	336000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-619000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	481000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-674000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	482000	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-674000	USD
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	482000	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-51000	USD
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	5652000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	5744000	USD
CY2018Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	116000	USD
CY2018Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	116000	USD
CY2018Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	151000	USD
CY2018Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	151000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-51000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1000	USD
CY2017Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	910000	USD
CY2018Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	211000	USD
CY2018Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	287000	USD
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	246000	USD
CY2017Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2018Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	42000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3551000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4011000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2083000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2425000	USD
CY2017Q3	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	7000	USD
CY2018Q3	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	7000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1118000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1088000	USD
CY2018Q2	us-gaap	Restricted Cash RestrictedCash	150000	USD
CY2018Q3	us-gaap	Restricted Cash RestrictedCash	150000	USD
CY2018Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	150000	USD
CY2018Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	150000	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-70826000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-70300000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-70344000	USD
CY2017Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5033000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6225000	USD
CY2017Q3	us-gaap	Revenues Revenues	5033000	USD
CY2018Q3	us-gaap	Revenues Revenues	6225000	USD
CY2017Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	683000	USD
CY2018Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	518000	USD
CY2017Q3	us-gaap	Share Based Compensation ShareBasedCompensation	564000	USD
CY2018Q3	us-gaap	Share Based Compensation ShareBasedCompensation	75000	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.844
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.871
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0198
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0282
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2480557	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.63
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1250	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.79
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.18
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5265000	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	14401000	USD
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2705845	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2687095	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.85
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.85
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	14401000	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2687095	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.69
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	56529	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	7500	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.10
CY2018Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.00
CY2018Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.00
CY2018Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.17
CY2018Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2018Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	13473000	USD
CY2018Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y6M
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y10M25D
CY2018Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y9M18D
CY2018Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	20000	shares
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	3000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	602000	USD
CY2018Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	269685	shares
CY2018Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	269685	shares
CY2018Q2	us-gaap	Treasury Stock Value TreasuryStockValue	1252000	USD
CY2018Q3	us-gaap	Treasury Stock Value TreasuryStockValue	1252000	USD
CY2018Q2	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	2103000	USD
CY2018Q3	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	2629000	USD
CY2018Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	151000	USD
CY2018Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	151000	USD
CY2017Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10982159	shares
CY2018Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12618021	shares
CY2017Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10982159	shares
CY2018Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11012281	shares

Files In Submission

Name	View Source	Status
0001628280-18-011874-index-headers.html	Edgar Link	pending
0001628280-18-011874-index.html	Edgar Link	pending
0001628280-18-011874.txt	Edgar Link	pending
0001628280-18-011874-xbrl.zip	Edgar Link	pending
csbr-20180731.xml	Edgar Link	completed
csbr-20180731.xsd	Edgar Link	pending
csbr-20180731_cal.xml	Edgar Link	unprocessable
csbr-20180731_def.xml	Edgar Link	unprocessable
csbr-20180731_lab.xml	Edgar Link	unprocessable
csbr-20180731_pre.xml	Edgar Link	unprocessable
csbr10-q7312018.htm	Edgar Link	pending
csbrq1731201810-qex311.htm	Edgar Link	pending
csbrq1731201810-qex312.htm	Edgar Link	pending
csbrq1731201810-qex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr

2018 Q3 Form 10-Q Financial Statement

#000162828018011874 Filed on September 14, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSBR CHAMPIONS ONCOLOGY, INC. Stock $csbr

2018 Q3 Form 10-Q Financial Statement

#000162828018011874 Filed on September 14, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr